First!The summit held by Qiantang promoted the future of the pharmaceutical industry!

On July 22, the first international MAH cooperation and innovation summit forum opened in Qiantang District, Chen Shifei, deputy director of the National Pharmaceutical Supervision and Administration Bureau, Li Xueyi, academician of the Chinese Academy of Engineering, the president of Wenzhou Medical University, academician of the National Academy of Sciences of Germany, and China University of Pharmacy University The principal came to Maode, Shao Rong, Executive Dean of the Academy of Pharmaceutical Supervision Sciences of China University of Pharmaceutical, and Yang Yan, president of the Provincial Medical Security Research Association, attended the forum from more than 60 experts, scholars, and supervisory agencies from the biomedical industry.

The opening ceremony was chaired by Zhu Zhiquan, former member of the Provincial Political Consultative Conference, former director of the Food and Drug Administration of Zhejiang Province, supervisors of the Chinese Pharmaceutical Society, honorary chairman of the Provincial Pharmaceutical Society, and chairman of the Provincial Traditional Chinese Medicine Big Health Federation. District leaders Shen Yanjun and Xu Jin attended.

This event lasted for two days. It was divided into 5 major forums to invite more than 60 experts, scholars, and heads of regulators to share the themes to attract thousands of people. The total number of online viewers has accumulated over 10,000.

The forum was sponsored by Zhejiang Pharmaceutical Lisalbility Hand -in -by Platform. The platform was jointly launched by the Zhejiang Pharmaceutical Association, Zhejiang Pharmaceutical Supervision and Management and Industrial Development Research Association, Zhejiang Pharmaceutical University Vocational University and Qiantang District People's Government. The current platform has been It has absorbed 1,856 membership companies, helping member companies to dock more than 900 times, and established the country's first MAH certificate transformation advance demonstration industrial park, and the park has settled in more than 30 biomedical companies.

The first international MAH cooperation and innovation summit forum focuses on the MAH system, focusing on the difficulty and solutions of the development of innovative drugs under the MAH regulatory and MAH system, and sharing my country's latest pharmaceutical industry policies and regulatory directions under the MAH system. Under the MAH system, how companies seize opportunities and lead the development trend of global pharmaceutical innovation.

The MAH system is called a drug listing license holder system, which is a major reform and transformation of my country's pharmaceutical registration system. Since 2016, it has gone through 6 years. From the initial conception of the comprehensive implementation of the later period, the emergence of the MAH system released the vitality of drug research and development with unprecedented situations, and helped the new drug innovation policy.

The development of the MAH system is inseparable from the opinions of the expert think tank, the docking of corporate practice and needs, the gathering and exchanges of talents, and the sharing and integration of data. The conference opened four important events related to the development of the industry in the future -the establishment of the expert committee of the Zhejiang Pharmaceutical Listing Located Platform, the release of the "MAH Blue Book", and the Zhejiang Provincial Pharmaceutical Review Center Talent Joint Training Base The unveiling and the release of the big data platform of "Medicine".

According to reports, 598 pharmaceutical production licenses have been approved in China. As the earliest pilot MAH system 10 provinces and cities, the number of drug production licenses approved by Zhejiang ranks at the forefront of the country. The convening of this conference will provide suggestions for further exploration, improvement, and development of the MAH system in my country.

At present, Qiantang District has gathered more than 1,500 biomedical companies, and 7 of the top ten pharmaceutical companies in the world have been settled here. There are more than 500 high -end talents in biomedicine, including 10 academicians and 3 talents of Peng Peng. Last year, the revenue of the life and health industry in the region was 47.3 billion yuan, accounting for about 50%of Hangzhou, showing a good trend of booming.

Next, Qiantang District will strengthen protection services, guide production capacity gatherings, promote the structural reform of the supply -side supply side of the pharmaceutical industry, fully promote the implementation of the MAH system, fully stimulate the vitality of biomedical research and development, and strive to promote the power of Qiantang in the province to promote the "two advances". Essence

- END -